Pulmatrix Announces Peer-Reviewed Publication Headache: The Journal Of Head And Face Pain, Clinical Results For Its Orally Inhaled DHE For Acute Migraine
Portfolio Pulse from Benzinga Newsdesk
Pulmatrix, Inc. (NASDAQ:PULM) announced the publication of clinical results for its orally inhaled DHE (PUR3100) for acute migraine in the peer-reviewed journal Headache: The Journal of Head and Face Pain. The study showed that PUR3100 has rapid systemic pharmacokinetics and improved safety and tolerability compared to intravenously administered DHE. The FDA has accepted an IND application for a Phase 2 study, making PUR3100 Phase 2-ready.
May 15, 2024 | 1:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pulmatrix's publication of clinical results for PUR3100 in a peer-reviewed journal and FDA's acceptance of an IND application for a Phase 2 study are positive developments. The study shows PUR3100's rapid systemic PK and improved safety, positioning it well for further clinical trials.
The publication in a peer-reviewed journal and FDA's acceptance of the IND application are significant milestones for Pulmatrix. These developments enhance the credibility and potential of PUR3100, likely leading to positive investor sentiment and a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100